Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 781 to 795 of 1244 results for pathway

  1. NICE is gearing up for the evaluation of further digital health technologies as pilot project produces first result

    Following the successful evaluation of Zio XT, developers of digital health technologies are encouraged to engage with NICE through one of several different routes.

  2. What is the relationship between midwifery staffing and outcomes in maternity settings in England, and what factors act as modifiers or confounders of the relationship between midwifery staffing and outcomes?

    maternal risk factors, neonatal needs, and stage of the maternity care pathway). - Environmental factors (for example, local geography...

  3. Early supported discharge in care home patients: What is the clinical and cost effectiveness of early supported discharge on mortality, quality of life and functional status in people with hip fracture who are admitted from a care home?

    months. There are no clinical trials to define the optimal rehabilitation pathway following hip fracture for these people and therefore...

  4. Surgical site infections: prevention and treatment (NG125)

    This guideline covers preventing and treating surgical site infections in adults, young people and children who are having a surgical procedure involving a cut through the skin. It focuses on methods used before, during and after surgery to minimise the risk of infection.

  5. Tofacitinib for treating active ankylosing spondylitis (TA920)

    Evidence-based recommendations on tofacitinib (Xeljanz) for treating active ankylosing spondylitis.

  6. Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments (TA970)

    Evidence-based recommendations on selinexor (Nexpovio) with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments in adults.

  7. Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults (TA245)

    Evidence-based recommendations on apixaban (Eliquis) for preventing venous thromboembolism after total hip or knee replacement in adults.

  8. PulmoVista 500 for monitoring ventilation in critical care (MIB203)

    NICE has developed a medtech innovation briefing (MIB) on PulmoVista 500 for monitoring ventilation in critical care .

  9. Airglove air warming system for venous access (MIB151)

    NICE has developed a medtech innovation briefing (MIB) on Airglove air warming system for venous access .

  10. moorLDLS-BI for burn depth assessment (MIB251)

    NICE has developed a medtech innovation briefing (MIB) on moorLDLS-BI for burn depth assessment .

  11. Achieving and demonstrating compliance with NICE TA and HST guidance

    of their treatment Providers publish their formulary, policies and care pathways to demonstrate that medicines and treatments...

  12. What is the natural history of people with a Likert score on MRI of less than 3 without biopsy at long-term follow‑up?

    the recommendations. As there was limited evidence on the most effective pathway for excluding clinically significant progression of...

  13. Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable (TA763)

    Evidence-based recommendations on daratumumab (Darzalex) with bortezomib, thalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is suitable.

  14. Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable (TA917)

    Evidence-based recommendations on daratumumab (Darzalex) with lenalidomide and dexamethasone for untreated multiple myeloma in adults, when a stem cell transplant is unsuitable.

  15. CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic (MIB219)

    NICE has developed a medtech innovation briefing (MIB) on CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic .